Evidence map›Paper›PMID 42743347›Full record

ReviewCirculation. Heart failure2026

A Recovery-Focused Framework for the Management of Cardiogenic Shock.

Christos P Kyriakopoulos, Iosif Taleb, Rana Hamouche, Eleni Tseliou, Stavros G Drakos

Abstract readReview
In one paragraph

Review in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christos P KyriakopoulosDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health and School of Medicine, Salt Lake City (C.P.K., R.H., E.T., S.G.D.).ORCID 0000-0001-9415-1245
Iosif TalebDivision of Cardiology, Department of Medicine, University of California San Diego, La Jolla (I.T.).ORCID 0000-0002-0029-5019
Rana HamoucheDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health and School of Medicine, Salt Lake City (C.P.K., R.H., E.T., S.G.D.).ORCID 0000-0002-9404-3866
Eleni TseliouDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health and School of Medicine, Salt Lake City (C.P.K., R.H., E.T., S.G.D.).ORCID 0000-0002-9350-2282
Stavros G DrakosDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Utah Health and School of Medicine, Salt Lake City (C.P.K., R.H., E.T., S.G.D.).ORCID 0000-0002-1223-327X

Funding

TRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6M
UCSD Integrated Cardiovascular Epidemiology FellowshipT32HL079891 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew A Allison · 2007 to 2026
$6.7M
Mechanism of Eccentric Cardiomyocyte Hypertrophy Secondary to Mitral RegurgitationR01HL166513 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos · 2023 to 2026
$2.4M
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart FailureR01HL135121 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE · 2017 to 2021
$1.9M
Cellular Remodeling in Heart Failure and after LVAD UnloadingR01HL132067 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE, SACHSE, FRANK BERND · 2017 to 2020
$1.5M
The Role of Glycosyl Ceramides in Heart Failure and RecoveryK08HL168315 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Eleni Tseliou · 2023 to 2026
$717k
BLRD VA I01 BX006306CSRD VA I01 CX002291NHLBI NIH HHS K08 HL168315NHLBI NIH HHS R01 HL132067NHLBI NIH HHS R01 HL135121NHLBI NIH HHS R01 HL166513NHLBI NIH HHS T32 HL007576NHLBI NIH HHS T32 HL079891
6 · The paper itself

Abstract

Cardiogenic shock describes a syndrome of systemic hypoperfusion due to insufficient cardiac output. Therapeutic interventions aim to restore systemic perfusion and oxygen delivery, relieve congestion, and reverse the primary culprit pathologies that precipitate shock. Cardiogenic shock care often emphasizes acute rescue and survival; however, survival does not always equal meaningful recovery. In this review, we propose a recovery-focused framework in which myocardial and end-organ recovery are treated as explicit, measurable targets. Building upon prior frameworks proposed for the management of shock, we organize cardiogenic shock management into four overlapping phases: salvage, optimization, stabilization, and de-escalation. Each phase addresses a distinct clinical question: can the patient be rescued, is perfusion and unloading sufficient to prevent further injury, is meaningful myocardial and end-organ recovery occurring, and is recovery durable enough to withdraw support? We synthesize current strategies and highlight emerging targets and research priorities spanning early identification and triage, integrated macro- and microcirculatory monitoring, phenotype-guided management, targeted metabolic and immunologic therapies, use of mechanical circulatory support as a recovery platform, and structured de-escalation of care.

Indexed as

HemodynamicsShock, CardiogenicHeart-Assist DevicesHumansMicrocirculationRecovery of FunctionTreatment Outcomeheart-assist devicesheart failurehemodynamic monitoringmicrocirculationmyocardial infarctionshock, cardiogenicventricular remodeling

Identifiers

PMID42743347
PMCPMC13676308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.